CVS Health’s first quarter results drew a significant positive market reaction, with performance driven by disciplined cost management, margin expansion, and continued improvement at Aetna. Management credited strong execution in medical cost containment and operational streamlining, particularly within the Health Care Benefits segment, as key factors. CEO David Joyner stated, “We are driving improved results at Aetna, while removing friction for members and providers.” Pharmacy & Consumer Wellness also benefited from increased prescription volumes and a focus on affordability initiatives, despite some impact from mild seasonal illness and regulatory price changes.
Is now the time to buy CVS? Find out in our full research report (it’s free for active Edge members).
CVS Health (CVS) Q1 CY2026 Highlights:
- Revenue: $100.4 billion vs analyst estimates of $94.44 billion (6.2% year-on-year growth, 6.3% beat)
- Adjusted EPS: $2.57 vs analyst estimates of $2.21 (16.5% beat)
- Adjusted EBITDA: $5.90 billion vs analyst estimates of $5.10 billion (5.9% margin, 15.8% beat)
- Management raised its full-year Adjusted EPS guidance to $7.40 at the midpoint, a 4.2% increase
- Operating Margin: 4.7%, up from 3.6% in the same quarter last year
- Locations: 8,908.6 at quarter end, down from 9,085 in the same quarter last year
- Same-Store Sales rose 2.8% year on year (14.2% in the same quarter last year)
- Market Capitalization: $121.4 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From CVS Health’s Q1 Earnings Call
- Justin Lake (Wolfe): Asked about Medicare Advantage rates for 2027 and the margin improvement trajectory. CEO David Joyner and President Steven Nelson reiterated confidence in reaching target margins by 2028, citing ongoing disciplined execution.
- Michael Cherny (Leerink Partners): Inquired about Health Services segment dynamics and PBM regulatory pressures. CFO Brian Newman and Co-President Prem Shah described early-year timing benefits but highlighted ongoing focus on affordability and transparency.
- Andrew Mok (Barclays): Questioned the pace and impact of AI investment and potential for share repurchases. CEO David Joyner detailed technology’s role in driving consumer engagement and operational efficiency, while Newman noted capital deployment will be evaluated throughout the year.
- Lisa Gill (JPM): Sought clarity on state-level PBM regulatory changes and resulting business impacts. Management outlined proactive regulatory adaptation, with Shah emphasizing the need for cost control, transparency, and innovative solutions in specialty pharmacy.
- George Hill (Deutsche Bank): Raised questions on GLP-1 market share and the evolving margin profile under cost-plus pricing. Joyner and Shah pointed to share gains in direct-to-consumer channels and a neutral impact from cost-based pricing models.
Catalysts in Upcoming Quarters
In the coming quarters, our team will closely monitor (1) the adoption and consumer impact of the Health100 digital platform, (2) progress on margin recovery goals in both Aetna and pharmacy segments amid ongoing regulatory changes, and (3) the scaling of value-based care initiatives such as Oak Street Health. The pace of biosimilar adoption and the company’s ability to navigate evolving PBM legislation will also be key markers of execution.
CVS Health currently trades at $95.17, up from $80.69 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
